Managing Information Overload - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Managing Information Overload
Companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise's diverse and discrete technology applications.


Pharmaceutical Technology Europe
Volume 23, Issue 8

Another technology that fits into the extraction and integration layer is data federation, or data virtualisation, whereby a department or business leader might grab snippets of information from different systems for quick access and analysis. This technology is most applicable for small quantities of data that don't require substantial transformation or cleansing. According to Burnett, data virtualisation enables users to quickly access data that is pertinent to their particular requirements.

Master data management, which gives users a single view of an important part of the business, such as a product or a customer, also fits into this layer. One example might be filling in missing pieces of data in a record or removing errors from a record. The final part of the extraction/integration stack is service-oriented architecture or data services. This is another way of breaking data into components that can be reused at various points throughout the organisation.

  • Information services is second from the top of the stack. For most users, this level is where the more familiar tools and applications such as search, retrieval, audit and forecast are found.
  • At the top of the stack is delivery, which focuses on making information easier for the user to digest and understand. Delivery allows information to be synthesised for a particular user, such as financial, project management and development or scientific research.

Conclusion

Regulatory information management involves far more than just tracking submissions. The processes and technologies used to enable successful regulatory information management help companies to consolidate their disparate systems and produce meaningful, holistic information that leads to better decision-making. The starting point is managing and structuring the data in a clear and consistent manner. Only by having clean, consistent and reliable data is it possible to build a broad picture of how an organisation's resources are currently being used and how they can be maximised in the future.

Adam Sherlock is director, Regulatory Solutions Group, at CSC Life Sciences.

References

1. S. Burnett, "The Information Management Imperative"(presentation given in London (UK), September 2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here